Bradley Canino
Stock Analyst at Stifel
(2.17)
# 1,505
Out of 4,502 analysts
71
Total ratings
39.06%
Success rate
-2.59%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Buy | $103 → $115 | $79.95 | +43.84% | 3 | Jul 10, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $42 | $24.63 | +70.52% | 4 | Jun 26, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $32 → $10 | $4.36 | +129.36% | 17 | Jun 18, 2024 | |
| MRUS Merus | Maintains: Buy | $90 → $99 | $54.32 | +82.25% | 7 | Jun 17, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $8 → $14 | $10.49 | +33.46% | 2 | Jun 3, 2024 | |
| CELC Celcuity | Maintains: Buy | $40 | $19.15 | +108.88% | 2 | May 16, 2024 | |
| CCCC C4 Therapeutics | Maintains: Buy | $13 → $14 | $6.44 | +117.39% | 4 | May 9, 2024 | |
| ARVN Arvinas | Maintains: Buy | $72 → $68 | $29.52 | +130.35% | 5 | May 8, 2024 | |
| CGEM Cullinan Oncology | Initiates: Buy | $40 | $19.91 | +100.90% | 1 | May 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Buy | $120 → $130 | $113.69 | +14.35% | 5 | Apr 26, 2024 | |
| AFMD Affimed | Maintains: Hold | $1 → $5 | $5.10 | -1.96% | 4 | Apr 1, 2024 | |
| ALXO ALX Oncology Holdings | Downgrades: Hold | $10 → $14 | $6.10 | +129.51% | 4 | Mar 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $35 → $55 | $44.04 | +24.89% | 4 | Feb 23, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $25 → $30 | $9.06 | +231.13% | 3 | Feb 22, 2024 | |
| BDTX Black Diamond Therapeutics | Upgrades: Buy | $2 → $10 | $6.23 | +60.51% | 4 | Jun 30, 2023 | |
| KURA Kura Oncology | Maintains: Buy | $24 → $25 | $20.78 | +20.31% | 2 | Jun 12, 2023 |
Nuvalent
Jul 10, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $79.95
Upside: +43.84%
Syndax Pharmaceuticals
Jun 26, 2024
Maintains: Buy
Price Target: $40 → $42
Current: $24.63
Upside: +70.52%
Zentalis Pharmaceuticals
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $4.36
Upside: +129.36%
Merus
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $54.32
Upside: +82.25%
Summit Therapeutics
Jun 3, 2024
Maintains: Buy
Price Target: $8 → $14
Current: $10.49
Upside: +33.46%
Celcuity
May 16, 2024
Maintains: Buy
Price Target: $40
Current: $19.15
Upside: +108.88%
C4 Therapeutics
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $6.44
Upside: +117.39%
Arvinas
May 8, 2024
Maintains: Buy
Price Target: $72 → $68
Current: $29.52
Upside: +130.35%
Cullinan Oncology
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $19.91
Upside: +100.90%
Blueprint Medicines
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $113.69
Upside: +14.35%
Affimed
Apr 1, 2024
Maintains: Hold
Price Target: $1 → $5
Current: $5.10
Upside: -1.96%
ALX Oncology Holdings
Mar 8, 2024
Downgrades: Hold
Price Target: $10 → $14
Current: $6.10
Upside: +129.51%
Kymera Therapeutics
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $44.04
Upside: +24.89%
Relay Therapeutics
Feb 22, 2024
Maintains: Buy
Price Target: $25 → $30
Current: $9.06
Upside: +231.13%
Black Diamond Therapeutics
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $6.23
Upside: +60.51%
Kura Oncology
Jun 12, 2023
Maintains: Buy
Price Target: $24 → $25
Current: $20.78
Upside: +20.31%